Nasdaq
$0.5150▲ 0.94%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $17.1MShares out 33.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
44- 1d agoAfter-hours26.10.24 05:01SC TO-I/AOther#●●●#●●●
Jasper Therapeutics, Inc.
Jasper Therapeutics is conducting a tender offer to purchase all 12,345,707 of its outstanding warrants issued in September 2025 for $0.324 in cash per warrant. The purpose of this offer is to reduce the number of common shares that would be issued upon warrant exercise, thereby providing greater certainty regarding the company's capital structure. The offer period expires on November 6, 2026, at 11:59 p.m. ET.…more
$0.5150+0.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoRegular26.10.20 22:33DEF 14AOther
Jasper Therapeutics, Inc.
Jasper Therapeutics will hold a special meeting of stockholders on November 13, 2026, to vote on the conversion of non-voting preferred stock into common stock, issued in connection with the acquisition of Kira Pharmaceuticals and a private placement. This proposal is intended to comply with Nasdaq listing rules and does not require a vote on the completed merger itself.…more
$0.5150+0.94%vs prev closeView filingShare - 10.15Pre-market26.10.15 21:008-KKey event
Jasper Therapeutics, Inc.
Jasper Therapeutics has completed patient enrollment for the IgA nephropathy (IgAN) cohort in its Phase 2 basket study evaluating vensobafusp alfa (KP104). The company expects to report initial interim data from the IgAN study by the end of 2026 and has expanded the study to include an FSGS cohort, with the first patient dosing anticipated in the first quarter of 2027.…more
$0.5150+0.94%vs prev closeView filingShare
43 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 21:01#●●●#●●●#●●●
Jasper Therapeutics Completes Phase 2 Enrollment for IgA Nephropathy
Jasper Therapeutics has finished enrolling 18 patients for its Phase 2 IgA nephropathy trial of vensobafusp alfa. Initial data from the study is expected to be released by the end of the year.…more
$0.5150+0.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.7Pre-market26.10.07 21:01
●●●●●●●● ●●●●● ●●●●●●
Jasper Therapeutics has announced a cash tender offer to purchase all 12,345,707 outstanding warrants at $0.324 per warrant. The offer is scheduled to expire on November 6.…more
$0.5150+0.94%vs prev closeShareBenzinga - 9.28After-hours26.09.29 05:48
●●●●●●●● ●●●●● ●●●●●●
Jasper Therapeutics CFO Herb Cross will resign effective October 9, 2026, with CEO Jeet Mahal stepping in as interim Principal Financial Officer. The company has reallocated key financial and accounting responsibilities among existing executives to ensure operational continuity.…more
$0.5150+0.94%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report